Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Crenezumab in Japanese Patients With Alzheimer's Disease
jRCT2080223155Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crenezumab in Alzheimer's disease (AD) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary safety and tolerability. Started Mar 2016; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223155.